Amylin Pharmaceuticals is moving on after rejecting Bristol-Myers Squibb's unsolicited $3.5 billion offer. The company reportedly is seeking other bids. Credit Suisse and Goldman Sachs are serving as financial advisers, sources said, while Skadden Arps is the legal adviser. Analysts see AstraZeneca, Merck & Co. and Takeda Pharmaceutical as potential buyers.
Published in Brief: